Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 7
1988 41
1989 53
1990 51
1991 64
1992 63
1993 95
1994 89
1995 83
1996 86
1997 91
1998 101
1999 101
2000 97
2001 89
2002 83
2003 78
2004 96
2005 111
2006 98
2007 102
2008 113
2009 122
2010 149
2011 154
2012 208
2013 151
2014 161
2015 168
2016 147
2017 118
2018 99
2019 47
2020 2
Text availability
Article attribute
Article type
Publication date

Search Results

3,058 results
Results by year
Filters applied: . Clear all
Page 1
Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins.
Liu L. Protein Cell 2018 - Review. PMID 28421387 Free PMC article.
There are many factors that can influence the pharmacokinetics (PK) of a mAb or Fc-fusion molecule with the primary determinant being FcRn-mediated recycling. ...
There are many factors that can influence the pharmacokinetics (PK) of a mAb or Fc-fusion molecule with the primary determinant being …
Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones?
Churcher I. J Med Chem 2018 - Review. PMID 29144739
Targeted protein degradation, using bifunctional small molecules (Protacs) to remove specific proteins from within cells, has emerged as a novel drug discovery strategy with the potential to offer therapeutic interventions not achievable with existing approaches. ...
Targeted protein degradation, using bifunctional small molecules (Protacs) to remove specific proteins from within cells, has emerged …
Defining extended half-life rFVIII-A critical review of the evidence
Mahlangu J, et al. Haemophilia 2018 - Review. PMID 29633467
INTRODUCTION: Recent haemophilia treatment advances include new recombinant FVIII (rFVIII) products with improved pharmacokinetic (PK) properties that aim to reduce the burden of prophylaxis. ...
INTRODUCTION: Recent haemophilia treatment advances include new recombinant FVIII (rFVIII) products with improved pharmacokinetic
Self-encapsulation and controlled release of recombinant proteins using novel silica-forming peptides as fusion linkers.
Abdelhamid MAA, et al. Int J Biol Macromol 2019. PMID 30576734
The fusion of SFPs to model fluorescent proteins directed their auto-encapsulation in wet sol-gel silica materials. Furthermore, the SFPs served as affinity linkers for the immobilization of recombinant proteins in silica. ...These new findings provide a simple and reproducible route for silica hybrid formation for in situ stable auto-encapsulation and the sustained release of recombinant proteins with potential applications in biotechnology....
The fusion of SFPs to model fluorescent proteins directed their auto-encapsulation in wet sol-gel silica materials. Furthermore, the …
Recombinant von Willebrand factor: a first-of-its-kind product for von Willebrand disease.
Singal M and Kouides PA. Drugs Today (Barc) 2016 - Review. PMID 28276537
A recombinant VWF (vonicog alfa, Vonvendi™; manufactured by Baxalta, now part of Shire) was approved by the U.S. Food and Drug Administration (FDA) in December 2015. This review will survey the literature based on a MEDLINE review on the safety, efficacy and pharmacokinetics of Vonvendi. It will also summarize the ongoing studies on Vonvendi available in the public domain. ...
A recombinant VWF (vonicog alfa, Vonvendi™; manufactured by Baxalta, now part of Shire) was approved by the U.S. Food and Drug Admini …
Pharmacokinetics of recombinant bifunctional fusion proteins.
Chen X, et al. Expert Opin Drug Metab Toxicol 2012 - Review. PMID 22428984 Free PMC article.
INTRODUCTION: The development of biotechnology has enabled the creation of various recombinant fusion proteins as a new class of biotherapeutics. ...Pharmacokinetic (PK) studies, which are critical components in preclinical and clinical drug development, have not been fully explored for fusion proteins. ...
INTRODUCTION: The development of biotechnology has enabled the creation of various recombinant fusion proteins as a new class …
Recombinant proteins for genetic disease.
Russell CS and Clarke LA. Clin Genet 1999 - Review. PMID 10450855
The availability of recombinant proteins and the development of appropriate delivery systems will result in more widespread use of these agents. ...This review will highlight advances in the use of recombinant proteins for genetic disease and future potential uses of recombinant proteins....
The availability of recombinant proteins and the development of appropriate delivery systems will result in more widespread us …
Pharmacokinetics, Safety, and Efficacy of Recombinant Factor VIII Fc Fusion Protein: A Practical Review.
Schafer K, et al. J Infus Nurs 2017 - Review. PMID 28030484
Recombinant factor VIII Fc fusion protein (rFVIIIFc) has a prolonged half-life compared with conventional rFVIII, and has demonstrated safety and efficacy for the prevention and treatment of bleeding episodes in phase 3 studies of patients with severe hemophilia A. ...
Recombinant factor VIII Fc fusion protein (rFVIIIFc) has a prolonged half-life compared with conventional rFVIII, and has demonstrate
[Advances of long-acting recombinant protein therapeutics].
Wei Y, et al. Sheng Wu Gong Cheng Xue Bao 2018 - Review. PMID 29577686 Chinese. Free article.
Some of the recombinant protein therapeutics with short half-life requires high frequent dose or injection, which results in poor patient compliance. This challenge has prompted the development of long-acting recombinant proteins in recent years. Four strategies and methods, including chemical modification, protein engineering, fusion proteins and protein glycosylation are used to modify protein molecule and finally obtain improved pharmacokinetics (PK) properties. ...
Some of the recombinant protein therapeutics with short half-life requires high frequent dose or injection, which results in poor pat …
Population pharmacokinetics of recombinant coagulation factor VIII-SingleChain in patients with severe hemophilia A.
Zhang Y, et al. J Thromb Haemost 2017 - Clinical Trial. PMID 28244200 Free article.
Essentials rVIII-SingleChain is a unique recombinant factor VIII (FVIII) molecule. A population pharmacokinetic model was based on FVIII activity of severe hemophilia A patients. ...SUMMARY: Background Single-chain recombinant coagulation factor VIII (rVIII-SingleChain) is a unique recombinant coagulation factor VIII molecule. ...
Essentials rVIII-SingleChain is a unique recombinant factor VIII (FVIII) molecule. A population pharmacokinetic model was base …
3,058 results
Jump to page
Feedback